These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 36302166)
1. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population. Alduaij W; Collinge B; Ben-Neriah S; Jiang A; Hilton LK; Boyle M; Meissner B; Chong L; Miyata-Takata T; Slack GW; Farinha P; Craig JW; Lytle A; Savage KJ; Villa D; Gerrie AS; Freeman CL; Gascoyne RD; Connors JM; Morin RD; Sehn LH; Mungall AJ; Steidl C; Scott DW Blood; 2023 May; 141(20):2493-2507. PubMed ID: 36302166 [TBL] [Abstract][Full Text] [Related]
2. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716 [TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907 [No Abstract] [Full Text] [Related]
4. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma. Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538 [TBL] [Abstract][Full Text] [Related]
5. High-grade B-cell lymphoma with Scott DW; King RL; Staiger AM; Ben-Neriah S; Jiang A; Horn H; Mottok A; Farinha P; Slack GW; Ennishi D; Schmitz N; Pfreundschuh M; Nowakowski GS; Kahl BS; Connors JM; Gascoyne RD; Ott G; Macon WR; Rosenwald A Blood; 2018 May; 131(18):2060-2064. PubMed ID: 29475959 [TBL] [Abstract][Full Text] [Related]
6. Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study). Hilton LK; Collinge B; Ben-Neriah S; Alduaij W; Shaalan H; Weng AP; Cruz M; Slack GW; Farinha P; Miyata-Takata T; Boyle M; Meissner B; Cook JR; Ondrejka SL; Ott G; Rosenwald A; Campo E; Amador C; Greiner TC; Raess PW; Song JY; Inghirami G; Jaffe ES; Weisenburger DD; Chan WC; Beiske K; Fu K; Delabie J; Pittaluga S; Iqbal J; Wright G; Sehn LH; Savage KJ; Mungall AJ; Feldman AL; Staudt LM; Steidl C; Rimsza LM; Morin RD; Scott DW Blood; 2024 Aug; 144(5):525-540. PubMed ID: 38701426 [TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G; J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305 [TBL] [Abstract][Full Text] [Related]
8. The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Hilton LK; Tang J; Ben-Neriah S; Alcaide M; Jiang A; Grande BM; Rushton CK; Boyle M; Meissner B; Scott DW; Morin RD Blood; 2019 Oct; 134(18):1528-1532. PubMed ID: 31527075 [TBL] [Abstract][Full Text] [Related]
9. Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma. Yuan CT; Chuang SS; Cheng PY; Chang K; Wang H; Tsai JH; Liau JY; Chou WC J Pathol Clin Res; 2022 Sep; 8(5):436-447. PubMed ID: 35715938 [TBL] [Abstract][Full Text] [Related]
10. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers. Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292 [TBL] [Abstract][Full Text] [Related]
11. Clinical significance of 'double-hit' and 'double-expression' lymphomas. Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842 [TBL] [Abstract][Full Text] [Related]
12. Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study. Urata T; Naoi Y; Jiang A; Boyle M; Sunami K; Imai T; Nawa Y; Hiramatsu Y; Yamamoto K; Fujii S; Yoshida I; Yano T; Chijimatsu R; Murakami H; Ikeuchi K; Kobayashi H; Tani K; Ujiie H; Inoue H; Tomida S; Yamamoto A; Kondo T; Fujiwara H; Asada N; Nishimori H; Fujii K; Fujii N; Matsuoka KI; Sawada K; Momose S; Tamaru JI; Nishikori A; Sato Y; Yoshino T; Maeda Y; Scott DW; Ennishi D Blood Adv; 2023 Dec; 7(24):7459-7470. PubMed ID: 37552496 [TBL] [Abstract][Full Text] [Related]
13. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry. Lešková K; Szépe P; Balhárek T; Barthová M; Janáková Ľ; Farkašová A; Plank L Neoplasma; 2022 Jul; 69(4):957-964. PubMed ID: 35652622 [TBL] [Abstract][Full Text] [Related]
14. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation. Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190 [TBL] [Abstract][Full Text] [Related]
15. Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. Cucco F; Barrans S; Sha C; Clipson A; Crouch S; Dobson R; Chen Z; Thompson JS; Care MA; Cummin T; Caddy J; Liu H; Robinson A; Schuh A; Fitzgibbon J; Painter D; Smith A; Roman E; Tooze R; Burton C; Davies AJ; Westhead DR; Johnson PWM; Du MQ Leukemia; 2020 May; 34(5):1329-1341. PubMed ID: 31844144 [TBL] [Abstract][Full Text] [Related]
16. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093 [TBL] [Abstract][Full Text] [Related]
17. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Hu S; Xu-Monette ZY; Tzankov A; Green T; Wu L; Balasubramanyam A; Liu WM; Visco C; Li Y; Miranda RN; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Slack GW; Gascoyne RD; Tu M; Variakojis D; Chen W; Go RS; Piris MA; Møller MB; Medeiros LJ; Young KH Blood; 2013 May; 121(20):4021-31; quiz 4250. PubMed ID: 23449635 [TBL] [Abstract][Full Text] [Related]
18. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified. Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026 [TBL] [Abstract][Full Text] [Related]
19. Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting. Thirunavukkarasu B; Bal A; Prakash G; Malhotra P; Singh H; Das A Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):49-55. PubMed ID: 34456240 [TBL] [Abstract][Full Text] [Related]
20. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]